R&D Insight

WHO Pipeline review / Roadmap for susceptibility testing developers

Dear All: Two useful papers have just been released — see titles and abstracts below my signature. Both are Open Access so please do download & read! And just for full disclosure, know that I’m a co-author on both. First, a working group organized by WHO has produced a comprehensive review of the clinical antimicrobial pipeline for both

Read More »

7 Nov 2017 FDA VRBPAC: Clinical development plan for a S. aureus vaccine (Part 1 of 3)

Addendum: This is the first in a 3-newsletters series on this topic. Go here and here for the next two newsletters. Finally, the results of the STRIVE trial have been published as Hassanzadeh et al. in Clinical Infectious Diseases, ciad218, https://doi.org/10.1093/cid/ciad218. Dear All:  I just learned that FDA’s Vaccines and Related Biological Products Committee (VRBPAC) will meet at

Read More »

ECCMID Symposium: Expediting antibacterial development: core lessons and key tools for a rocky road

Dear All: GARDP and CARB-Xed co-sponorsored yesterday an ECCMID symposium entitled “Expediting antibacterial development: core lessons and key tools for a rocky road.” A detailed tour of the many lessons we’ve learned in recent years, the program was (follow the links to download the talks): Marco Cavaleri (EMA): EU regulatory tools for expedited antibacterial development programmes EMA has

Read More »

NHS England Antibiotic Procurement Pilot: Call for applications!

Dear All, As has been discussed in recent newsletters (link), the UK National Institute for Health and Care Excellence (NICE) and NHS England launched a joint project July 2019 to test a payment model for antibiotic products, based on a product’s value to the NHS, rather than how much is used. This goal of the

Read More »

SPIDAAR & ATLAS: Data sharing via AMR Surveillance partnerships

Dear All, Building on the ATLAS database (link) that provides open access to data from 2004 to the present out of the multiple surveillance programs that Pfizer has run over that interval, Wellcome Trust and Pfizer have just announced that the underlying database will also be used to support SPIDAAR (Surveillance Partnership to Improve Data

Read More »

EPA (Part 4): Further resources

Dear All, We’ve had a fascinating series of 3 prior newsletters, all triggered by EPA’s concept note for “Pesticides; Concept for a Framework To Assess the Risk to the Effectiveness of Human and Animal Drugs Posed by Certain Antibacterial or Antifungal Pesticides; Notice of Availability and Request for Comment”: The 27 Sep 2023 newsletter taught us the idea

Read More »

EPA (part 2, streptomycin!) / $104m ARPA-H BAA and AMR project

This is the second of a 4-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, and finally a 4th newsletter (27 Jan 2024) containing some additional resources. Dear All (OK, so now it’s 5 newsletters in as

Read More »

JPIAMR: AMR Interventions call for both fungi and bacteria!

Dear All, Happy New Year! I hope you were able to relax with friends and family during the year-end festivities! I have a small backlog of notes that will follow over the next few days but for tonight we have a brief note about a funding opportunity with a short timeline. JPIAMR have today opened an

Read More »
Scroll to Top